TECX Tectonic Therapeutic
- 49.160
- +1.325+2.77%
- 50.000
- +0.840+1.71%
Tectonic Therapeutic News
Tectonic Therapeutic To Present on December 3rd, 2024 at the Piper Sandler Healthcare Conference
Tectonic Therapeutic Price Target Announced at $65.00/Share by Raymond James
Raymond James Initiates Tectonic Therapeutic(TECX.US) With Buy Rating, Announces Target Price $65
Tectonic Therapeutic Initiated With an Outperform at Raymond James
Tectonic Therapeutic Inc. Faces Challenges With Australian Subsidiary Amid Regulatory and Operational Risks
Tectonic Therapeutic | 10-Q: Q3 2024 Earnings Report
Insiders Continue to Buy Tectonic Therapeutic, Inc. (NASDAQ:TECX) and Now Own 41% Shares
Wells Fargo Maintains Tectonic Therapeutic(TECX.US) With Buy Rating, Maintains Target Price $79
Wells Fargo Maintains Tectonic Therapeutic(TECX.US) With Buy Rating, Raises Target Price to $79
Tectonic Therapeutic Is Maintained at Outperform by Leerink Partners
Tectonic Therapeutic Analyst Ratings
Leerink Partners Maintains Tectonic Therapeutic(TECX.US) With Buy Rating, Raises Target Price to $69
Leerink Partners Raises Tectonic Therapeutic's Price Target to $69 From $49, Outperform Rating Maintained
Tectonic Therapeutic Announces Positive Phase 1a Results in AHA 2024 Presentation for TX45, a Long-acting, Fc-Relaxin Fusion Protein
Tectonic Therapeutic: Promising Phase 1a Results and Strong Financial Health Justify Buy Rating
AVROBIO GAAP EPS of -$1.20
TD Cowen Sticks to Their Buy Rating for Tectonic Therapeutic (TECX)
Express News | Tectonic Therapeutic Inc: Expected to Provide Cash Runway Into Mid-2027
Tectonic Therapeutic | 8-K: Tectonic Therapeutic Announces Third Quarter 2024 Financial Results and Recent Business Highlights
Tectonic Therapeutic Reports Q3 EPS ($1.20), Consensus (82c)
Analysis
Price Target
No Data
No Data